Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Capital Intensity

The Capital Intensity Ratio of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 22, 2026 is 401.00 %. In the previous year, Capital Intensity Ratio was 282.00 % — a change of 42.20% (higher).

Capital Intensity

401.00 %

YoY

42.20%

Last updated:

Capital Intensity Ratio of Shanghai InnoStar Bio-tech Co is 2025 401.00 % . Capital Intensity Ratio of Shanghai InnoStar Bio-tech Co was 2024 282.00 % . It decreases by 42.20% higher compared to the previous year.

The Shanghai InnoStar Bio-tech Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2021
309.85 CNY
Jan 1, 2022
303.37 CNY
Jan 1, 2023
267.27 CNY
Jan 1, 2024
282.00 CNY
Jan 1, 2025
401.00 CNY
The Shanghai InnoStar Bio-tech Co Capital Intensity history
YEARCapital IntensityYoY
401.00 %+42.20%
282.00 %+5.51%
267.27 %-11.90%
303.37 %-2.09%
309.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Capital Intensity Ratio of Shanghai InnoStar Bio-tech Co is 401.00 % in 2025.

Capital Intensity Ratio of Shanghai InnoStar Bio-tech Co changed from 282.00 % to 401.00 %, representing a 42.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co